Becker's Healthcare September 19, 2024
On Sept. 24, Novo Nordisk CEO Lars Fruergaard Jørgensen is slated to testify at a Senate committee hearing about the costs for Wegovy and Ozempic.
The hearing comes after months of disagreements between Denmark-based Novo Nordisk and the Senate Committee on Health, Education, Labor and Pensions. The former says the United States’ complex pharmaceutical industry is causing high prices, while the latter says the drugmaker is acting on “corporate greed.”
Wegovy is a weight loss medicine with a monthly list price of $1,349, and Ozempic is a Type 2 diabetes drug with a monthly list price of $969. After months of Sen. Bernie Sanders said major generic drugmakers told him their companies could sell the two blockbuster drugs for...
Today's Sponsors
Today's Sponsor